Abstract: A powder comprises one or more monoclonal antibody, one or more cyclodextrin, and a compound selected from carboxymethyl dextran (CMD), one or more basic amino acid, or both. The powder may be compressed to form a compressed shape such as minitabs. A method of forming a powder comprises the steps of: 1) providing one or more monoclonal antibody, one or more cyclodextrin, and a compound selected from carboxymethyl dextran (CMD), one or more basic amino acid, or both; 2) forming a solution comprising the monoclonal antibody, cyclodextrin, CMD, and amino acid; and 3) drying the solution. This complexed mAb was found to be stable in resisting aggregation during the process of evaporative solidification and compression at pressures up to 10.5 kbar. Also, the complexed mAb has more resistance towards proteolysis than that of uncomplexed mAb.

Abstract: The present invention relates to a method and covalent bonding process for fixing tritiated water into a polystyrene based product for the permanent elimination of tritiated water from the environment.

Abstract: The present invention relates to a method and covalent bonding process for fixing tritiated water into a polystyrene based product for the permanent elimination of tritiated water from the environment.

Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

Abstract: The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.

Abstract: An antibiofilm complex formed of a polyvinylpyrrolidone (PVP) backbone, iodine anchored to the PVP backbone, Rifampin anchored to the PVP backbone, and a second antibiotic selected from the group consisting of Tobramycin and Gentamicin anchored to the PVP backbone.

Abstract: The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.

Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

Abstract: The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine.

Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

Abstract: The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine.

Abstract: Mono- and di-iodinated nonoxynol-9-derivatives and methods for their use are disclosed.

Abstract: Mono- and di-iodinated nonoxynol-9-derivatives and methods for their use are disclosed.

Abstract: Novel 2'-onium salts of paclitaxel act as prodrugs in mammalian patients to yield paclitaxel in vivo. Methods of synthesizing these onium salts are disclosed, as are methods of treating patients suffering from paclitaxel-responsive diseases by administering effective amounts of the onium salts and pharmaceutical compositions containing the novel salts which are suitable for administration to patients requiring paclitaxel therapy.

Abstract: A method of reducing corneal scarring or fibroblast proliferation comprises applying to an area of a subject's eye afflicted with the condition a corneal scar-fibroblast proliferation-reducing amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect. A method of reducing neovascularization of corneal scar tissue comprises applying to an area of a subject's eye afflicted with the condition a neovascularization-inhibitory amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect.

Abstract: The present invention relates to a hard capsule made from a material such as gelatin, starch or a hydrophilic polymer. The capsule of the present invention is formulated into a delivery system which incorporates pharmacologically active components in three or more distinct compartments. When three compartments are utilized in the capsule, the outer compartment incorporates a drug and excipients into a layer which coats the outer part of the capsule. This layer represents the rapid release portion of the delivery system. The intermediate compartment comprises a powder formulation comprised of a drug and excipients which represents the intermediary speed release portion of the delivery system. The innermost compartment incorporates the active ingredient or ingredients in a multiparticulate form, such as small pellets, and represents the slow release component of the delivery system.

Abstract: A compound of the formula ##STR1## wherein R and R' together represent a primary or a secondary aliphatic amine. Also described are elastase enzyme inhibitory compositions including a carrier and an elastase enzyme inhibiting amount of the compounds of the invention. A method of selectively inhibiting the enzyme elastase in an animal or a human in need of such treatment includes administering to the animal or human an enzyme elastase inhibiting amount of one of the compounds of the invention or a composition thereof.

Abstract: A composition which has potent anti-HIV activity. The composition is a high energy coprecipitate of nonoxynol-9 oligomers, polyvinyl-pyrrolidone (PVP) and iodine or PVP-I and shows a pronounced synergistic, anti-HIV effect between the compounds of the composition. The invention also includes paper and plastic products coated with the composition of the invention.

Abstract: A composition which is a contraceptive with potent anti-HIV activity. The composition is a high energy coprecipitate of nonoxynol-9 oligomers, polyvinylpyrrolidone (PVP) and iodine or PVP-I and shows a pronounced synergistic, anti-HIV effect between the compounds of the composition. A method of obtaining a contraceptive and anti-HIV environment in a female comprising administering to said female an effective amount of a high energy coprecipitate.

Abstract: Pharmaceutical compositions and methods of inhibiting the enzyme elastase and increasing the biological half-life and/or potency in terms of inhibitory activity of the enzyme elastase of peptide compounds is achieved by use of a polymer of the formula P--(L--R).sub.q wherein P is a polymer containing at least one unit of the formula (A.sub.n B.sub.n) wherein A.sub.n B.sub.n is substantially nonbiodegradable, and has an average molecular weight of about 1,000 to 5,000 daltons, L is a covalent bond or a linker group and R is a peptide.